450 related articles for article (PubMed ID: 30029896)
1. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
[TBL] [Abstract][Full Text] [Related]
2. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
[TBL] [Abstract][Full Text] [Related]
3. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.
Denholm JT; McBryde ES; Eisen D; Street A; Matchett E; Chen C; Shultz TR; Biggs B; Leder K
Intern Med J; 2017 Dec; 47(12):1433-1436. PubMed ID: 29224209
[TBL] [Abstract][Full Text] [Related]
4. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
Sterling TR; Scott NA; Miro JM; Calvet G; La Rosa A; Infante R; Chen MP; Benator DA; Gordin F; Benson CA; Chaisson RE; Villarino ME;
AIDS; 2016 Jun; 30(10):1607-15. PubMed ID: 27243774
[TBL] [Abstract][Full Text] [Related]
5. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
Bliven-Sizemore EE; Sterling TR; Shang N; Benator D; Schwartzman K; Reves R; Drobeniuc J; Bock N; Villarino ME;
Int J Tuberc Lung Dis; 2015 Sep; 19(9):1039-44, i-v. PubMed ID: 26260821
[TBL] [Abstract][Full Text] [Related]
6. Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
Tseng SY; Huang YS; Chang TE; Perng CL; Huang YH
J Chin Med Assoc; 2021 Nov; 84(11):993-1000. PubMed ID: 34747900
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
[TBL] [Abstract][Full Text] [Related]
9. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
Sandul AL; Nwana N; Holcombe JM; Lobato MN; Marks S; Webb R; Wang SH; Stewart B; Griffin P; Hunt G; Shah N; Marco A; Patil N; Mukasa L; Moro RN; Jereb J; Mase S; Chorba T; Bamrah-Morris S; Ho CS
Clin Infect Dis; 2017 Oct; 65(7):1085-1093. PubMed ID: 28575208
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.
Shepardson D; Marks SM; Chesson H; Kerrigan A; Holland DP; Scott N; Tian X; Borisov AS; Shang N; Heilig CM; Sterling TR; Villarino ME; Mac Kenzie WR
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1531-7. PubMed ID: 24200264
[TBL] [Abstract][Full Text] [Related]
11. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Sterling TR; Moro RN; Borisov AS; Phillips E; Shepherd G; Adkinson NF; Weis S; Ho C; Villarino ME;
Clin Infect Dis; 2015 Aug; 61(4):527-35. PubMed ID: 25904367
[TBL] [Abstract][Full Text] [Related]
12. Improved treatment completion with shorter treatment regimens for latent tuberculous infection.
Macaraig MM; Jalees M; Lam C; Burzynski J
Int J Tuberc Lung Dis; 2018 Nov; 22(11):1344-1349. PubMed ID: 30355415
[TBL] [Abstract][Full Text] [Related]
13. Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials.
Moro RN; Scott NA; Vernon A; Tepper NK; Goldberg SV; Schwartzman K; Leung CC; Schluger NW; Belknap RW; Chaisson RE; Narita M; Machado ES; Lopez M; Sanchez J; Villarino ME; Sterling TR
Ann Am Thorac Soc; 2018 May; 15(5):570-580. PubMed ID: 29393655
[TBL] [Abstract][Full Text] [Related]
14. Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection.
Borisov AS; Bamrah Morris S; Njie GJ; Winston CA; Burton D; Goldberg S; Yelk Woodruff R; Allen L; LoBue P; Vernon A
MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(25):723-726. PubMed ID: 29953429
[TBL] [Abstract][Full Text] [Related]
15. Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events.
Lin SY; Chiu YW; Lu PL; Hwang SJ; Chen TC; Hsieh MH; Chen YH
J Microbiol Immunol Infect; 2019 Feb; 52(1):158-162. PubMed ID: 29907535
[TBL] [Abstract][Full Text] [Related]
16. Completion Rate and Safety of Tuberculosis Infection Treatment With Shorter Regimens.
Cruz AT; Starke JR
Pediatrics; 2018 Feb; 141(2):. PubMed ID: 29363561
[TBL] [Abstract][Full Text] [Related]
17. Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates.
Knoll BM; Nog R; Wu Y; Dhand A
Infection; 2017 Jun; 45(3):335-339. PubMed ID: 28276008
[TBL] [Abstract][Full Text] [Related]
18. Completion Rates, Adverse Effects, and Costs of a 3-Month and 9-Month Treatment Regimen for Latent Tuberculosis Infection in California Inmates, 2011-2014.
Wheeler C; Mohle-Boetani J
Public Health Rep; 2019; 134(1_suppl):71S-79S. PubMed ID: 31059418
[TBL] [Abstract][Full Text] [Related]
19. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
Simkins J; Abbo LM; Camargo JF; Rosa R; Morris MI
Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035
[TBL] [Abstract][Full Text] [Related]
20. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
Surey J; Stagg HR; Yates TA; Lipman M; White PJ; Charlett A; Muñoz L; Gosce L; Rangaka MX; Francis M; Hack V; Kunst H; Abubakar I
BMC Infect Dis; 2021 Jan; 21(1):90. PubMed ID: 33478428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
